Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,919
datasets available to search
ShareScore release 0.9.0
Dataset results
3,919 results for “cohort”
Plate 1. Figs. 2–8 in Discovery and Genetic Characterization of Single Cohort Adult Colonies With Male Aggregations, and Preliminary Evidence for Lekking in a Malagasy Kite Spider (Isoxya,
Plate 1. Figs. 2–8. Female: dorsal (Fig. 2), ventral (Fig. 3), side (Fig. 4); epigyne: ventral (Fig 5), posterior (Fig. 6), spermatheca dorsal (Fig. 7); line drawing: epigyne ventral (Fig. 8).
Fig. 27 in Discovery and Genetic Characterization of Single Cohort Adult Colonies With Male Aggregations, and Preliminary Evidence for Lekking in a Malagasy Kite Spider (Isoxya,
Fig. 27. Membership probability for each individual to the nine web colonies (A–I) based on the discriminant analysis of principal components clustering from unlinked SNPs.
raw data - Association between Bristol Stool Form Scale and the risk of colorectal polyp recurrence: A retrospective cohort study
Open the record for dataset details and reuse information.
Anticipate Cohort Study Data
Open the record for dataset details and reuse information.
Frequency of biologically-defined AD in relation to age, sex, APOEε4 and cognitive impairment in a prospective cohort study
<p><b>Objective:</b> <span> To assess the frequency of biologically-defined Alzheimer's disease (AD) in relation to age, sex and <i>APOEε4</i>, as well as rates of discordance between clinically- and biologically defined AD. </span></p> <p><b>Methods:</b> <span>We assessed cognitively unimpaired (CU) elderly (n=166), amnestic MCI (n=77) and probable AD dementia (n=62) subjects who underwent evaluation by dementia specialists and neuropsychologists in addition to amyloi</span>d-PET with [<sup>18</sup>F]AZD4694<span> and tau-PET with [<sup>18</sup>F]MK6240. Individuals were grouped according to their AD biomarker profile. Positive predictive value for biologically-defined AD was assessed in relation to clinical diagnosis. Frequency of AD biomarker profiles were assessed using logistic regressions with odds ratios and 95% CIs.</span></p> <p><b>Results:</b> <span>The clinical diagnosis of probable AD dementia demonstrated good agreement with biologically-defined AD (positive predictive value: 85.2%). 7.88% of CU elderly subjects were positive for both amyloid-PET and tau-PET. Frequency of biologically-defined AD increased with age (OR: 1.14; p<0.0001) and frequency of <i>APOEε4</i> allele carriers (Single <i>ε4: </i>OR: 3.82; <i>p</i><0.0001; Double <i>ε4: </i>OR: 17.55, <i>p</i><0.0001). </span></p> <p><b>Discussion:</b> While we observed <span>strong, but not complete, agreement between clinically-defined "probable AD" dementia and biomarker positivity for both amyloid</span>-β<span> and tau, we also observed that biologically-defined AD was not rare in CU elderly. A</span>bnormal tau-PET was almost exclusively observed in individuals with abnormal amyloid-PET. <span>Our results highlight that even in tertiary care memory clinics, detailed evaluation by dementia specialists systematically underestimates the frequency of biologically-defined AD and related entities. </span></p>
A retrospective cohort study on effects of antenatal steroids on respiratory morbidity for term elective Caesarean sections in South Asian women
<p>Respiratory distress (RD) is higher among newborns born by caesarean section (CS) at term. RCOG recommend steroid administration for CS prior to 39 weeks. Evidence for effectiveness of steroids for neonatal RD at term is inconclusive. The racial differences are yet to be studied. </p> <p>A single center retrospective cohort study was conducted in Colombo, Sri Lanka form December 2016 to February 2019. All mothers delivered by CS between 37+0 and 38+6 weeks were included in the study. Mothers with severe maternal hypertension, severe fetal rhesus sensitization, evidence of intrauterine infection, multiple pregnancies and those who received steroids due to other indications at a prior gestation and were excluded. Cohort was subdivided according to administration of IM dexamethasone prior to CS. Primary outcomes measured were RD, admissions to neonatal intensive care unit (NICU) and special care baby unit (SCBU). Neonatal infections and maternal duration of hospital stay was recorded as secondary outcome measures. </p> <p>560 patients were included in the study. 23.2% of patients received antenatal corticosteroids. Incidence of RD, NICU admissions and SCBU admissions in the study cohort was 10%, 0.9%, 2.7% respectively. RR for developing RD in the steroid group compared to non-steroid group was 2.67 (1.64-4.35). NICU and SCBU admissions was needed by 4.6% in steroid group and 3.3% in non-steroid group without a significant difference (p=0.464). A significantly higher number of babies in the steroid group needed IV antibiotics. Average days the mothers were admitted in the hospital was 2.45 days (SD 1.424) for steroid group and 1.4 days (SD 0.856) for the non-steroid group (p < 0.001).</p> <p>There is a significant increase in the respiratory morbidity in the dexamethasone administered south Asian mothers at term prior to CS. However, this effect has no clinical significance since the admission to NICU and SCBU were not significantly different.</p>
Dataset from: Sport improved 18-month results in a prospective cohort of 785 adolescents with idiopathic scoliosis braced full-time
<p>Dataset from a still non-published study titled "Sport improved 18-month results in a prospective cohort of 785 adolescents with idiopathic scoliosis braced full-time"</p>
SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort, South Africa, July 2020–September 2021
<p>Early results of the PHIRST-C study seroprevalence results in South Africa</p>
Dataset: Elisa cohort study on SARS-CoV-2 transmission
<p>The Elisa study is a population-based cohort study in Lübeck and the surrounding area (northern Germany) with the aim to determine the prevalence and influencing factors of infections with the Sars-CoV2 over a one-year period. The study collected data from April 2020 to February 2021. A cohort of 3000 randomly selected individuals were screened by swab (PCR) for active corona infection and blood draws were performed to determine antibodies at seven time points. In addition, continuous app-based questionnaires were administered to study participants regarding symptoms, behavior, and social factors.</p> <p>The data set consists of a file with baseline variables and examination results for the 3000 participants and another file with the continuous survey data (90,000 interviews).</p>
Supplemental material for: Clinical and neuroimaging outcomes of direct endovascular thrombectomy vs. bridging therapy in large vessel occlusion patients: a secondary analysis of SELECT cohort study
<p><b>Objective:</b> To evaluate the comparative safety and efficacy of direct endovascular thrombectomy(dEVT) compared to bridging therapy(BT:IV-tPA+EVT) and assess if BT potential benefit relates to stroke severity, size and initial presentation to EVT vs. non-EVT center.</p> <p><b>Methods:</b> In a prospective multicenter cohort-study of imaging selection for endovascular thrombectomy[SELECT], anterior-circulation large vessel occlusion (LVO) patients presenting to EVT-capable centers within 4.5hours from last-known-well were stratified into BT vs. dEVT.<b><i> </i></b>The primary outcome was 90-day functional independence[modified Rankin Scale(mRS)=0-2]. Secondary outcomes included a shift across 90-day mRS grades, mortality, symptomatic intracranial hemorrhage. We also performed subgroup-analyses according to initial presentation to EVT-capable center (direct versus transfer), stroke severity and baseline infarct core volume.</p> <p><b>Results:</b> We identified 226 LVOs (54%:men, mean age:65.6±14.6years, median NIHSS-score: 17, 28% received dEVT). Median time from arrival to groin-puncture did not differ in BT-patients when presenting directly[dEVT:1.43 (IQR=1.13-1.90) hours vs. BT:1.58(IQR=1.27-2.02)hours,p=0.40] or transferred to EVT-capable centers[dEVT:1.17 (IQR: 0.90-1.48) hours vs. BT:1.27 (IQR: 0.97-1.87) hours,p=0.24]. BT was associated with higher odds of 90-day functional independence (57% vs. 44%,aOR=2.02,95%CI:1.01-4.03,p=0.046) and functional improvement (adjusted cOR=2.06,95%CI:1.18-3.60,p=0.011), and lower likelihood of 90-day mortality (11% vs. 23%,aOR: 0.20,95%CI:0.07-0.58,p=0.003). No differences in any other outcomes were detected. In subgroup-analyses, BT patients with baseline NIHSS-scores<15 had higher functional independence likelihood compared to dEVT (aOR=4.87,95%CI:1.56-15.18,p=0.006); this association was not evident for patients with NIHSS-scores≥15 (aOR=1.05,95%CI:0.40-2.74,p=0.92). Similarly, functional outcomes improvements with BT were detected in patients with core volume strata (Ischemic core <50cc: aOR: 2.10, 95% CI:1.02-4.33, p=0.044 vs ischemic core ≥50cc: aOR: 0.41,95% CI:0.01-16.02,p=0.64) and transfer status (transferred: aOR: 2.21,95% CI:0.93-9.65,p=0.29 vs direct to EVT center: aOR:1.84,95%CI:0.80-4.23,p=0.15). </p> <p><b>Conclusions:</b> Bridging therapy appears to be associated with better clinical outcomes, especially with milder NIHSS-scores, smaller presentation core volumes and those who were "dripped and shipped".</p> <p><b>Classification of Evidence: </b>This study provides Class III evidence that for patients with ischemic stroke from anterior-circulation LVO within 4.5 hours from last-known-well, bridging therapy compared to direct endovascular thrombectomy leads to better 90-day functional outcomes.</p>
FURIN promoter methylation predicts the risk of incident diabetes: A prospective analysis in the Gusu cohort
<p><strong>Background:</strong> Furin has been associated with diabetes but the underlying mechanisms are unclear. As a mediator linking fixed genome and dynamic environment, DNA methylation of its coding gene FURIN may be involved. Here, we aimed to examine the prospective association between DNA methylation in FURIN promoter and incident diabetes during 4 years of follow-up in Chinese adults.</p> <p><strong>Methods:</strong> DNA methylation levels in FURIN promoter were quantified by target bisulfite sequencing using peripheral blood from 1836 participants in the Gusu cohort who were free of diabetes at baseline. To examine the association between DNA methylation levels in FURIN promoter and incident diabetes, we constructed a logistic regression model adjusting for the conventional factors. Multiple testing was controlled by adjusting for the total number of CpG sites assayed using the false-discovery rate approach.</p> <p><strong>Results:</strong> Among the 1836 participants free of diabetes at baseline, 109 (5.94%) participants developed diabetes during the average of 4 years of follow-up. Hypermethylation at two of the eight CpG sites assayed in the FURIN promoter was associated with an increased risk of diabetes, after multivariable adjustment and multiple testing correction. Every 5% increment in methylation levels at CpG1 and CpG2 were associated with a 22% (OR=1.22, 95%CI: 1.05-1.43, P=0.009, q=0.038) and 39% (OR=1.39, 95%CI: 1.08-1.77, P=0.009, q=0.038) higher risk of incident diabetes, respectively. The gene-based association analysis revealed that DNA methylation at multiple CpG loci was jointly associated with incident diabetes (P<0.001). Using the average methylation level of the 8 CpG loci in FURIN promoter revealed a similar association (OR=1.28, 95% CI: 1.02–1.62, P=0.037).</p> <p><strong>Conclusions:</strong> These results suggested that the hypermethylation levels in FURIN promoter were associated with an increased risk for incident diabetes in Chinese adults.</p>
Data and code for the manuscript titled "Persistence of SARS-CoV-2 immunity, Omicron's footprints, and projections of epidemic resurgences in South African population cohorts"
<p>Data and code for the manuscript titled “Persistence of SARS-CoV-2 immunity, Omicron’s footprints, and projections of epidemic resurgences in South African population cohorts”</p>
Long-term health-related quality of life, healthcare utilisation and back-to-work activities in Intensive Care Unit survivors: prospective confirmatory study from the Frisian Aftercare Cohort
<p>More substantial information on recovery after Intensive Care Unit (ICU) admission is urgently needed. In a previous retrospective study, the proportion of non-recovery patients was 44%. The aim of this prospective follow-up study was to evaluate changes Health-Related Quality of Life (HRQoL) in the first year after ICU-admission. Long-stay adult ICU-patients (≥ 48 hours) were included. HRQoL was evaluated with the Dutch translation of the RAND-36 item Health Survey (RAND-36) at baseline via proxy measurement, and at three, six, and twelve months after ICU admission. Subsequently, the relation between physical functioning, healthcare utilisation, and work activities was explored. </p>
Data from: Early prediction of in-hospital mortality in patients with congestive heart failure in intensive care unit: a retrospective observational cohort study
<p class="MsoNormal">Objective: Congestive heart failure (CHF) is a clinical syndrome in which heart disease progresses to a severe stage. Risk assessment and early diagnosis of death in patients with CHF are critical to patient prognosis and treatment. The purpose of this study was to establish a nomogram predicting in-hospital death for CHF patients in the ICU.</p> <p>Design: A retrospective observational cohort study.</p> <p>Setting and participants: The data of study from 30,411 CHF patients in the Medical Information Mart for Intensive Care (MIMIC-IV) database and the eICU Collaborative Research Database (eICU-CRD).</p> <p>Primary outcome: In-hospital mortality.</p> <p>Results: The inclusion criteria were met by 15983 subjects, whose in-hospital mortality rate was 12.4%. Multivariate analysis determined that the independent risk factors were age, race, norepinephrine, dopamine, phenylephrine, vasopressin, <a>mechanical</a> <a>ventilation</a>, intubation, HepF, heart rate, respiratory rate, temperature, SBP, AG, BUN, creatinine, chloride, MCV, RDW, and WBC. The C-index of the nomogram (0.767, 95%CI: 0.759–0.779) was <a>superior</a> to that of the traditional SOFA, APSIII and GWTGHF score, indicating its discrimination power. Calibration plots demonstrated that the predicted results are in good agreement with the observed results. The decision curves of the derivation and validation sets both had net benefits.</p> <p>Conclusion: The twenty independent risk factors for in-hospital mortality of CHF patients were age, race, norepinephrine, dopamine, phenylephrine, vasopressin, <a>mechanical</a> <a>ventilation</a>, intubation, HepF, heart rate, respiratory rate, temperature, SBP, AG, BUN, creatinine, chloride, MCV, RDW, and WBC. The nomogram that included these factors accurately predicted the in-hospital mortality of CHF patients. The novel nomogram has the potential to be a clinical practice aided predictive tool for predicting and assessing mortality in CHF patients in the ICU.</p>
Coronary atherosclerotic burden assessed by SYNTAX scores and outcomes in surgical, percutaneous, or medical strategies: A retrospective cohort study
<div><span><strong>Introduction</strong></span></div> <div> </div> <div> <span>Coronary atherosclerotic burden and SYNTAX score (SS) are predictors of cardiovascular events.</span> </div> <div> </div> <div><span><strong>Objectives</strong></span></div> <div> </div> <div> <span>To investigate the value of SYNTAX scores (SS, SSII and residual SS [rSS]) for predicting cardiovascular events in patients with coronary artery disease (CAD).</span> </div> <div> </div> <div><strong><span>Design</span></strong></div> <div> </div> <div> <span>Retrospective cohort study.</span> </div> <div> </div> <div><strong><span>Setting</span></strong></div> <div> </div> <div> <span>Single tertiary centre.</span> </div> <div><strong> </strong></div> <div><strong><span>Participants</span></strong></div> <div> </div> <div> <span>Medicine, Angioplasty or Surgery Study (MASS) database patients with stable multivessel CAD and preserved ejection fraction.</span> </div> <div> </div> <div> <span>Interventions</span><span> CAD patients undergoing coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), or medical treatment (MT) alone from January 2002 to December 2015.</span> </div> <div> </div> <div> <span>Primary and secondary outcomes</span><span> Primary: 5-year all-cause mortality. Secondary: composite of all-cause death, myocardial infarction, stroke, and subsequent coronary revascularization at 5 years.</span> </div> <div> </div> <div><strong><span>Results</span></strong></div> <div> </div> <div> <span>A total of 1,719 patients underwent PCI (n = 573), CABG (n = 572), or MT (n = 574) alone. </span><span>The SS was not considered an independent predictor of 5-year mortality in the PCI </span><span>(low, intermediate and high SS 6.5%, 6.8% and 4.3%, respectively, p=0.745)</span><span>, CABG </span><span>(low, intermediate and high SS 5.7%, 8.0% and 12.1%, respectively, p=0.194)</span><span> and MT </span><span>(low, intermediate and high SS 6.8%, 6.9% and 6.5%, respectively, p=0.993)</span><span> cohorts. The SSII (low, intermediate and high SSII, 3.6% vs. 7.9% vs. 10.5%, respectively, p <0.001) was associated with a higher mortality risk in the overall population. Within each treatment strategy, SSII was associated with a significant 5-year mortality rate, especially in CABG patients with higher SSII (</span><span>low, intermediate and high SSII, </span><span>1.8%, 9.7% and 10.0%, respectively, </span><span>p = 0.004) and in MT patients with high SSII (</span><span>low, intermediate and high SSII, 5.0%, 4.7% and 10.8%, respectively,</span><span> p = 0.031). </span><span>SSII demonstrated a better predictive accuracy for mortality compared with SS and rSS </span><span>(c-index = 0.62)</span><span>. </span> </div> <div> </div> <div><span><strong>Conclusions</strong></span></div> <div> </div> <div><span>Coronary atherosclerotic burden alone was not associated with significantly increased risk of all-cause mortality. The SSII better discriminates the risk of death. </span></div>
St. Jude Lifetime Study Cohort dataset for multilevel characteristics of cumulative symptom burden in young survivors of childhood cancer
<p>The dataset contains variables from the St. Jude Lifetime Cohort Study used in the study of multilevel characteristics of cumulative symptom burden in young survivors of childhood cancer in Horan et al., 2024 (DOI:<a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2818384" target="_blank" rel="noopener">10.1001/jamanetworkopen.2024.10145</a>). </p> <p><strong>When using downloaded data, please cite corresponding paper and this repository:</strong></p> <ol> <li>Horan MR, Srivastava DK, Choi J, et al. Multilevel characteristics of cumulative symptom burden in young survivors of childhood cancer. <em>JAMA Netw Open.</em> 2024;7(5):e2410145. doi:10.1001/jamanetworkopen.2024.10145</li> <li>Horan MR, Srivastava DK, Choi J, et al. (2018). St. Jude Lifetime Study Cohort Dataset for multilevel characteristics of cumulative symptom burden in young survivors of childhood cancer (Version 1) [Data set]. 2024. Zenodo. http://doi.org/10.5281/zenodo.11474180</li> </ol> <p><strong>Funding:</strong></p> <p>The research reported in the manuscript was supported by the US National Cancer Institute under award numbers U01CA195547, R01CA238368, T32CA225590, and P30CA021765. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.</p>
Incidence and Predictive Factors of Hyperventilation Syndrome in Patients after COVID 19 pneumonia: A Prospective Cohort Study
Open the record for dataset details and reuse information.
Data from: Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae: A retrospective cohort study
<p><strong>Purpose:</strong> Infection by carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKP) has high mortality. There is no clear optimal therapeutic choice for pneumonia caused by CRKP. The aim of this study was to compare the clinical outcomes and safety of the standard doses of polymyxin B-based regimens vs tigecycline-based regimens and to identify risk factors for mortality.</p> <p><strong>Methods:</strong><strong> </strong>This retrospective cohort study included patients with pneumonia caused by CRKP for three years. The primary outcomes were 7-day bacterial eradication rate and 14- and 28-day all-cause mortality. The secondary outcome was incidence of acute kidney injury.</p> <p><strong>Results:</strong><strong> </strong>Seventy-three patients were included in this study, 29 in the<strong> </strong>polymyxin B-based combination therapy group and 44 in tigecycline-based combination therapy group. There were no significant differences between the two groups in terms of the 7-day bacterial eradication rate (31.0% vs 20.5%, <em>P</em>=0.409), the 14-day all-cause mortality (37.9% vs 22.7%, <em>P</em>=0.160), and the incidence of acute kidney injury (14.3% vs 6.8%, <em>P</em>=0.526). The 28-day all-cause mortality in the polymyxin B-based therapy group was higher than in the tigecycline-based group (75.9% vs 45.5%, <em>P</em>=0.010). Binary logistic regression analysis revealed that male and previous use of carbapenems were independent factors associated with 28-day all-cause mortality for patients treated with polymyxin B (<em>P</em><0.05).</p> <p><strong>Conclusions:</strong><strong> </strong>Polymyxin B-based combination therapy at the standard dose should be used with caution for patients with CRKP-induced pneumonia, especially for men who used carbapenems prior to CRKP detection.</p>
Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort
<p>Background: While numerous epidemiologic studies have found an association between higher serum 25-hydroxyvitamin D [25(OH)D] concentrations and lower breast cancer risk, few have assessed this association for concentrations >40 ng/ml.</p> <p> </p> <p>Objective: To investigate the relationship between 25(OH)D concentration and breast cancer risk across a broad range of 25(OH)D concentrations among women aged 55 years and older.</p> <p> </p> <p>Methods: Analyses used pooled data from two randomized clinical trials (N=1129, N=2196) and a prospective cohort (N=1713) to examine a broad range of 25(OH)D concentrations. The outcome was diagnosis of breast cancer during the observation periods (median: 4.0 years). Three analyses were conducted: 1) Incidence rates were compared according to 25(OH)D concentration from <20 to ≥60 ng/ml (<50 to ≥150 nmol/L), 2) Kaplan-Meier plots were developed and 3) multivariate Cox regression was used to examine the association between 25(OH)D and breast cancer risk using multiple 25(OH)D measurements.</p> <p> </p> <p>Results: Within the pooled cohort (N=5038), 77 women were diagnosed with breast cancer (age-adjusted incidence: 512 cases per 100,000 person-years). Results were similar for the three analyses. First, comparing incidence rates, there was an 82% lower incidence rate of breast cancer for women with 25(OH)D concentrations ≥60 vs <20 ng/ml (Rate Ratio=0.18, <em>P</em>=0.006). Second, Kaplan-Meier curves for concentrations of <20, 20-39, 40-59 and ≥60 ng/ml were significantly different (<em>P</em>=0.02), with the highest proportion breast cancer-free in the ≥60 ng/ml group (99.3%) and the lowest proportion breast cancer-free in the <20 ng/ml group (96.8%). The proportion with breast cancer was 78% lower for ≥60 vs <20 ng/ml (<em>P</em>=0.02). Third, multivariate Cox regression revealed that women with 25(OH)D concentrations ≥60 ng/ml had an 80% lower risk of breast cancer than women with concentrations <20 ng/ml (HR=0.20, <em>P</em>=0.03), adjusting for age, BMI, smoking status, calcium supplement intake, and study of origin.</p> <p> </p> <p>Conclusions: Higher 25(OH)D concentrations were associated with a dose-response decrease in breast cancer risk with concentrations ≥60 ng/ml being most protective.</p>
Predictors of depression, anxiety and stress indicators in a cohort of women with chronic pelvic pain data set
<p>Data set for submission of paper 'Predictors of depression, anxiety and stress indicators in a cohort of women with chronic pelvic pain'</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.